US FDA Neuroscience Office In Spotlight With Donanemab Delay, Relyvrio Trial Failure

 
• By Sue Sutter
  
Crossbow
FDA's Office of Neuroscience is feeling some recoil from its use of regulatory flexibility in two neurodegenerative diseases. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from Product Reviews